DaShenLin Pharmaceutical Group Co., Ltd.

Informe acción SHSE:603233

Capitalización de mercado: CN¥17.4b

DaShenLin Pharmaceutical Group Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Guoqiang Ke

Chief Executive Officer (CEO)

CN¥2.3m

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO5.8yrs
Participación del CEO0.02%
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva1.8yrs

Actualizaciones recientes de la dirección

Recent updates

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

CEO

Guoqiang Ke (42 yo)

5.8yrs

Permanencia

CN¥2,308,800

Compensación

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019 and serves as DIrector since February 03, 2023. He was Deputy General Manager of DaShenLin Pharmaceutic...


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Guoqiang Ke
GM & Director1.8yrsCN¥2.31m0.025%
CN¥ 4.3m
Qun Fei Tan
Deputy GM & Director1.8yrsCN¥2.05m0.024%
CN¥ 4.1m
Zhi Hui Chen
Chairman of Supervisory Board & Deputy Director of Human Resources Department - Guangdong Provinceno datasin datos0.012%
CN¥ 2.1m
Yun Feng Ke
Chairman of the Boardno dataCN¥2.49m21.3%
CN¥ 3.7b
Guo Liu
Independent Directorno dataCN¥73.40ksin datos
Zu Yao Su
Independent Directorno dataCN¥80.00ksin datos
Jie Li
Directorno datasin datossin datos
Li Ping Lu
Independent Directorno dataCN¥80.00ksin datos
Jinshu Shi
Staff Supervisorno datasin datos0.00055%
CN¥ 95.8k
Wensheng Chen
Supervisor1.8yrssin datossin datos

1.8yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de 603233 no se considera experimentada (1.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.